CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts rate CorMedix a “Moderate Buy”: Six of eight analysts recommend buying the stock, while two rate it a hold. The average 12-month price target is $14.86.
• Second-quarter results beat expectations: Revenue reached $101.9 million versus the $96.0 million consensus estimate, while earnings were $0.29 per share compared with expectations of $0.28. The company maintained its 2026 revenue outlook but raised adjusted EBITDA guidance.
• Growth catalysts remain in focus: CorMedix expects to submit a supplemental filing for its fungal-disease treatment by the third quarter, potentially expanding its commercial opportunity. The stock was trading up 14.6%, though institutional investors and hedge funds own only 34.18% of shares.

CorMedix Inc (NASDAQ:CRMD - Get Free Report) has earned an average rating of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $14.8571.

Several equities analysts have commented on the stock. Zacks Research raised shares of CorMedix from a "strong sell" rating to a "hold" rating in a research note on Friday, May 15th. Needham & Company LLC upped their price target on shares of CorMedix from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, April 27th. D. Boral Capital reiterated a "buy" rating and issued a $14.00 price objective on shares of CorMedix in a report on Monday, April 27th. Citizens Jmp reiterated a "market outperform" rating and set a $19.00 price objective on shares of CorMedix in a research note on Tuesday, April 28th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of CorMedix in a report on Tuesday.

Hedge Funds Weigh In On CorMedix

Several hedge funds have recently modified their holdings of the company. Financial Management Professionals Inc. bought a new stake in shares of CorMedix in the 4th quarter worth $25,000. Comerica Bank boosted its stake in CorMedix by 454.6% during the third quarter. Comerica Bank now owns 2,690 shares of the company's stock valued at $31,000 after buying an additional 2,205 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in CorMedix during the second quarter valued at about $42,000. Kestra Advisory Services LLC acquired a new position in CorMedix during the fourth quarter worth about $49,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in CorMedix by 666.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company's stock worth $51,000 after acquiring an additional 3,813 shares during the period. 34.18% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Q2 results exceeded expectations: CorMedix reported revenue of approximately $101.9 million, ahead of the roughly $96 million consensus estimate, while earnings reached $0.29 per share versus estimates ranging from $0.24 to $0.26. Net income was $26.0 million, and adjusted EBITDA was $58.7 million. CorMedix second-quarter financial results
• Positive Sentiment: Profitability outlook improved: The company maintained its fiscal 2026 revenue outlook while raising adjusted EBITDA guidance, signaling stronger operating leverage and cash-generation potential as sales grow. CorMedix Q2 2026 earnings call transcript
• Positive Sentiment: Potential pipeline catalyst: Chief Executive Officer Joe DeGennaro said CorMedix expects to submit a supplemental filing by the third quarter for use of its fungal-disease treatment. Regulatory progress could expand the company’s commercial opportunity beyond its current business. CorMedix supplemental filing and earnings reaction
• Neutral Sentiment: Revenue guidance remains broadly in line: Fiscal 2026 revenue guidance of $325 million to $345 million brackets the consensus estimate of approximately $334.7 million. The unchanged revenue outlook is offset by the higher EBITDA forecast, leaving the overall guidance update constructive but not a major top-line revision. CorMedix Q2 earnings and revenue estimates

CorMedix Trading Up 14.6%

NASDAQ:CRMD opened at $8.14 on Friday. The stock has a market cap of $638.58 million, a price-to-earnings ratio of 3.82 and a beta of 1.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.74 and a current ratio of 2.97. CorMedix has a 1 year low of $6.13 and a 1 year high of $14.96. The business has a fifty day moving average of $8.16 and a 200-day moving average of $7.65.

CorMedix (NASDAQ:CRMD - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. The business had revenue of $101.93 million for the quarter, compared to analysts' expectations of $96.04 million. CorMedix had a net margin of 45.25% and a return on equity of 45.57%. Equities analysts predict that CorMedix will post 0.51 earnings per share for the current year.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company's lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source